Advertisement
Advertisement

SWTX

SWTX logo

SpringWorks Therapeutics Inc

36.01
USD
-1.71
-4.53%
Dec 18, 15:59 UTC -5
Closed
...

SpringWorks Therapeutics Inc Profile

About

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.

Info & Links

CEO

Saqib Islam

Headquarters

100 WASHINGTON BOULEVARD
STAMFORD, CT 06902, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

93

Employees

305

SpringWorks Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

2.68B

Enterprise Value

2.59B

Enterprise Value/EBITDA(ttm)

-8.71

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

21.03

Price to Book(mrq)

5.34

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

70.85%

Operating Margin(ttm)

-203.09%

Profit Margin(ttm)

-147.85%

Return on Equity(ttm)

-48.21%

Return on Invested Capital(ttm)

-47.68%

Return on Assets(ttm)

-42.19%

Income Statement

Revenue(ttm)

130.04M

Revenue Per Share(ttm)

1.75

Gross Profit(ttm)

123.04M

EBITDA(ttm)3

-297.71M

Net Income Available to Common(ttm)

-275.16M

Diluted EPS(ttm)

-3.88

Share Statistics

Beta (5Y Monthly)

0.86

52-Week Change

13.74%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

74.39M

Dividend Yield

0.00%

Float4

68.72M

% Held by Insiders

7.61%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

376.62M

Total Cash Per Share(mrq)

5.06

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.16%

Quick Ratio(mrq)

6.02%

Book Value Per Share(mrq)

7.16

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.97

Free Cash Flow(ytd)

-149.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement